STX-241 FIH (F60087CI101)

RMC-LUNG-101A

RMC-LUNG-101

LB100

RMC-6291-101

STX-721-101

StrateGIST 1 (IDRX-42-001)

D6900C00001

CA1201001

M22TGA

CTLR-101

IMC-F106C-101 (PRAME)

TCD17620

MCLA-129-CL01

D9570C00001

GO43860

XL092-001

SGNPDL1V-001

INCB 123667-101

PROACTIVE

1479-0001

CyPep-1

VHIO17002

MCLA-128-CL01

KEYNOTE 158

DESTINY-Lung03

A Phase I/II Study of MCLA-128, a Full Length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients With Solid Tumors



<ul class="wp-block-list">
<li>Code NKI: M14MCL </li>



<li>Code firma: MCLA-128-CL01</li>



<li>Code clinicaltrials.gov: NCT02912949</li>
</ul>



Principal Investigator



Dr. F.L. Opdam



Drugs 



Zenocutuzumab (MCLA-128; Her2-Her3 inhibitor)



<ul class="wp-block-list">
<li>Group F: non small cell lung cancer with NRG1 fusion &#8211; open</li>



<li>Group G&nbsp;: pancreatic cancer with NRG1 fusion &#8211; open</li>



<li>Group H: other solid tumors with NRG1 fusion &#8211; closed</li>
</ul>



<h2 class="wp-block-heading">Summary</h2>



This is a Phase I/II, open-label, multi-center, multi-national, dose escalation, single agent study to assess the safety, tolerability, PK, PD, immunogenicity and anti-tumor activity of zenocutuzumab (MCLA-128) in patients with solid tumors harboring an NRG1 fusion.



Read more on <a href="https://www.clinicaltrials.gov/ct2/show/NCT02912949?term=MCLA-128-CL01&amp;draw=2&amp;rank=1" data-type="URL" data-id="https://www.clinicaltrials.gov/ct2/show/NCT02912949?term=MCLA-128-CL01&amp;draw=2&amp;rank=1">clinicaltrials.gov</a>



<h2 class="wp-block-heading">Patient population</h2>



Tumor type: NSCLC, non small cell lung cancer, lung cancer / pancreatic cancer, pancreatic carcinoma Tumor subtype: lung adenocarcinoma Tumor characteristics: NRG1 fusion